Multiplexed analysis of antibody secreting cells for enhanced function first antibody discovery

The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization.

Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The company will also develop nanovial-based multiepitope sequencing readouts as proof-of-concept, demonstrating how high-throughput nanovial technology combined with sequencing can provide earlier and more detailed insights into antibody-antigen interactions during the antibody discovery process. Both work streams aim to address inefficiencies in monoclonal antibody development by enabling efficient, cost-effective functional screening of individual antibody-secreting cells at scale.

The award funds a Phase I Small Business Innovation Research project. Performance occurs in California. The period of performance runs from the award date through June 30, 2027.

Abstract

Monoclonal antibodies (MABS) have emerged as pivotal tools in modern medicine, offering significant therapeutic and diagnostic benefits. Despite their importance, the development of MAB-based molecules is often hindered by inefficient and protracted processes, limiting their application and utility. Partillion bioscience seeks to address these challenges through its innovative nanovials, which promise to democratize advanced cellular assays at single-cell resolution. The company's award-winning technology from ucla enables efficient and cost- effective functional screening of single cells, accelerating the discovery and characterization of antibody candidates. In this proposal we outline two specific aims to enhance our nanovial based antibody discovery workflow to further accelerate the development of MABS. Specific aim 1 focuses on engineering novel nanovial formulations to allow the usage streptavidin- antigen complexes as detection agents thereby increasing the plexability of our assays. This involves exploring alternative chemistries to retain the functionality and versatility of our original biotin based nanovial formulation while unlocking compatibility with streptavidin-antigen complexes. Specific aim 2 aims to develop nanovial-based multiepitope sequencing readouts as a proof-of-concept demonstration of the ability to provide detailed insights into antibody- antigen interactions earlier in the antibody discovery process. This approach leverages the high- throughput capabilities of nanovials and the precision of sequencing technologies to offer a more comprehensive understanding of antibody behavior. In conclusion, partillion bioscience's nanovial technology represents a significant advancement in the field of antibody discovery and characterization. By addressing the current inefficiencies in MAB development, partillion's innovations have the potential to expedite the translation of potent monoclonal antibodies into clinical and diagnostic applications. The successful implementation of these specific aims will not only enhance the capabilities of the nanovial platform but also contribute to the broader goal of advancing healthcare through improved biologic therapies.